EUnetHTA Roadmap and its Implications on Biotech/ Pharma Manufacturers
Exploring new ways to navigate Health Technology Assessments--a vital, but complicated part of the development of health technologies in Europe.
The Health Technology Assessment (HTA) is a crucial process that evaluates the added value of health technologies, including drugs, medical devices and procedures. However, the creation of multiple HTA agencies across Europe has resulted in significant variability, leading to lack of harmonization, collaboration and sharing of HTA findings across different EU countries.
Syneos Health experts examine the challenges posed by the presence of the many HTA agencies in Europe and how manufacturers can overcome these hurdles. In addition, they examine recent EU regulations meant to address this issue and analyze how they could affect patients’ ability to access new treatments and therapies.
Download the white paper.
Related Content
Looking for exclusive insight?
